Effects of Palmitoylethanolamide (PEA) on Nociceptive, Musculoskeletal and Neuropathic Pain: Systematic Review and Meta-Analysis of Clinical Evidence
Some 30–50% of the global population and almost 20% of the European population actually suffer from chronic pain, which presents a tremendous burden to society when this pain turns into a disability and hospitalization. Palmitoylethanolamide (PEA) has been demonstrated to improve pain in preclinical...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-08-01
|
| Series: | Pharmaceutics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4923/14/8/1672 |
| _version_ | 1827617657756581888 |
|---|---|
| author | Damiana Scuteri Francesca Guida Serena Boccella Enza Palazzo Sabatino Maione Juan Francisco Rodríguez-Landa Lucia Martínez-Mota Paolo Tonin Giacinto Bagetta Maria Tiziana Corasaniti |
| author_facet | Damiana Scuteri Francesca Guida Serena Boccella Enza Palazzo Sabatino Maione Juan Francisco Rodríguez-Landa Lucia Martínez-Mota Paolo Tonin Giacinto Bagetta Maria Tiziana Corasaniti |
| author_sort | Damiana Scuteri |
| collection | DOAJ |
| description | Some 30–50% of the global population and almost 20% of the European population actually suffer from chronic pain, which presents a tremendous burden to society when this pain turns into a disability and hospitalization. Palmitoylethanolamide (PEA) has been demonstrated to improve pain in preclinical contexts, but an appraisal of clinical evidence is still lacking. The present study aimed at addressing the working hypothesis for the efficacy of PEA for nociceptive musculoskeletal and neuropathic pain in the clinical setting. The systematic search, selection and analysis were performed in agreement with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 recommendations. The primary outcome was pain reduction, as measured by a pain assessment scale. The secondary outcome was improvement in quality of life and/or of parameters of function. The results obtained for a total of 933 patients demonstrate the efficacy of PEA over the control (<i>p</i> < 0.00001), in particular in six studies apart from the two randomized, double-blind clinical trials included. However, the results are downgraded due to the high heterogeneity of the studies (I<sup>2</sup> = 99%), and the funnel plot suggests publication bias. Efficacy in achieving a reduction in the need for rescue medications and improvement in functioning, neuropathic symptoms and quality of life are reported. Therefore, adequately powered randomized, double-blind clinical trials are needed to deepen the domains of efficacy of add-on therapy with PEA for chronic pain. PROSPERO registration: CRD42022314395. |
| first_indexed | 2024-03-09T09:51:07Z |
| format | Article |
| id | doaj.art-9aac98d2412f48aaa57629b95fb114aa |
| institution | Directory Open Access Journal |
| issn | 1999-4923 |
| language | English |
| last_indexed | 2024-03-09T09:51:07Z |
| publishDate | 2022-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceutics |
| spelling | doaj.art-9aac98d2412f48aaa57629b95fb114aa2023-12-02T00:10:02ZengMDPI AGPharmaceutics1999-49232022-08-01148167210.3390/pharmaceutics14081672Effects of Palmitoylethanolamide (PEA) on Nociceptive, Musculoskeletal and Neuropathic Pain: Systematic Review and Meta-Analysis of Clinical EvidenceDamiana Scuteri0Francesca Guida1Serena Boccella2Enza Palazzo3Sabatino Maione4Juan Francisco Rodríguez-Landa5Lucia Martínez-Mota6Paolo Tonin7Giacinto Bagetta8Maria Tiziana Corasaniti9Pharmacotechnology Documentation and Transfer Unit, Preclinical and Translational Pharmacology, Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Rende, ItalyDepartment of Experimental Medicine, Pharmacology Division, University of Campania “L. Vanvitelli”, 80138 Naples, ItalyDepartment of Experimental Medicine, Pharmacology Division, University of Campania “L. Vanvitelli”, 80138 Naples, ItalyDepartment of Experimental Medicine, Pharmacology Division, University of Campania “L. Vanvitelli”, 80138 Naples, ItalyDepartment of Experimental Medicine, Pharmacology Division, University of Campania “L. Vanvitelli”, 80138 Naples, ItalyLaboratorio de Neurofarmacología, Instituto de Neuroetología, Universidad Veracruzana, Xalapa 91190, MexicoDirección de Investigaciones en Neurociencias, Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz, Mexico City 03440, MexicoRegional Center for Serious Brain Injuries, S. Anna Institute, 88900 Crotone, ItalyPharmacotechnology Documentation and Transfer Unit, Preclinical and Translational Pharmacology, Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Rende, ItalyDepartment of Health Sciences, University “Magna Graecia” of Catanzaro, 88100 Catanzaro, ItalySome 30–50% of the global population and almost 20% of the European population actually suffer from chronic pain, which presents a tremendous burden to society when this pain turns into a disability and hospitalization. Palmitoylethanolamide (PEA) has been demonstrated to improve pain in preclinical contexts, but an appraisal of clinical evidence is still lacking. The present study aimed at addressing the working hypothesis for the efficacy of PEA for nociceptive musculoskeletal and neuropathic pain in the clinical setting. The systematic search, selection and analysis were performed in agreement with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 recommendations. The primary outcome was pain reduction, as measured by a pain assessment scale. The secondary outcome was improvement in quality of life and/or of parameters of function. The results obtained for a total of 933 patients demonstrate the efficacy of PEA over the control (<i>p</i> < 0.00001), in particular in six studies apart from the two randomized, double-blind clinical trials included. However, the results are downgraded due to the high heterogeneity of the studies (I<sup>2</sup> = 99%), and the funnel plot suggests publication bias. Efficacy in achieving a reduction in the need for rescue medications and improvement in functioning, neuropathic symptoms and quality of life are reported. Therefore, adequately powered randomized, double-blind clinical trials are needed to deepen the domains of efficacy of add-on therapy with PEA for chronic pain. PROSPERO registration: CRD42022314395.https://www.mdpi.com/1999-4923/14/8/1672palmitoylethanolamidePEAnociceptive painneuropathic painclinical setting |
| spellingShingle | Damiana Scuteri Francesca Guida Serena Boccella Enza Palazzo Sabatino Maione Juan Francisco Rodríguez-Landa Lucia Martínez-Mota Paolo Tonin Giacinto Bagetta Maria Tiziana Corasaniti Effects of Palmitoylethanolamide (PEA) on Nociceptive, Musculoskeletal and Neuropathic Pain: Systematic Review and Meta-Analysis of Clinical Evidence Pharmaceutics palmitoylethanolamide PEA nociceptive pain neuropathic pain clinical setting |
| title | Effects of Palmitoylethanolamide (PEA) on Nociceptive, Musculoskeletal and Neuropathic Pain: Systematic Review and Meta-Analysis of Clinical Evidence |
| title_full | Effects of Palmitoylethanolamide (PEA) on Nociceptive, Musculoskeletal and Neuropathic Pain: Systematic Review and Meta-Analysis of Clinical Evidence |
| title_fullStr | Effects of Palmitoylethanolamide (PEA) on Nociceptive, Musculoskeletal and Neuropathic Pain: Systematic Review and Meta-Analysis of Clinical Evidence |
| title_full_unstemmed | Effects of Palmitoylethanolamide (PEA) on Nociceptive, Musculoskeletal and Neuropathic Pain: Systematic Review and Meta-Analysis of Clinical Evidence |
| title_short | Effects of Palmitoylethanolamide (PEA) on Nociceptive, Musculoskeletal and Neuropathic Pain: Systematic Review and Meta-Analysis of Clinical Evidence |
| title_sort | effects of palmitoylethanolamide pea on nociceptive musculoskeletal and neuropathic pain systematic review and meta analysis of clinical evidence |
| topic | palmitoylethanolamide PEA nociceptive pain neuropathic pain clinical setting |
| url | https://www.mdpi.com/1999-4923/14/8/1672 |
| work_keys_str_mv | AT damianascuteri effectsofpalmitoylethanolamidepeaonnociceptivemusculoskeletalandneuropathicpainsystematicreviewandmetaanalysisofclinicalevidence AT francescaguida effectsofpalmitoylethanolamidepeaonnociceptivemusculoskeletalandneuropathicpainsystematicreviewandmetaanalysisofclinicalevidence AT serenaboccella effectsofpalmitoylethanolamidepeaonnociceptivemusculoskeletalandneuropathicpainsystematicreviewandmetaanalysisofclinicalevidence AT enzapalazzo effectsofpalmitoylethanolamidepeaonnociceptivemusculoskeletalandneuropathicpainsystematicreviewandmetaanalysisofclinicalevidence AT sabatinomaione effectsofpalmitoylethanolamidepeaonnociceptivemusculoskeletalandneuropathicpainsystematicreviewandmetaanalysisofclinicalevidence AT juanfranciscorodriguezlanda effectsofpalmitoylethanolamidepeaonnociceptivemusculoskeletalandneuropathicpainsystematicreviewandmetaanalysisofclinicalevidence AT luciamartinezmota effectsofpalmitoylethanolamidepeaonnociceptivemusculoskeletalandneuropathicpainsystematicreviewandmetaanalysisofclinicalevidence AT paolotonin effectsofpalmitoylethanolamidepeaonnociceptivemusculoskeletalandneuropathicpainsystematicreviewandmetaanalysisofclinicalevidence AT giacintobagetta effectsofpalmitoylethanolamidepeaonnociceptivemusculoskeletalandneuropathicpainsystematicreviewandmetaanalysisofclinicalevidence AT mariatizianacorasaniti effectsofpalmitoylethanolamidepeaonnociceptivemusculoskeletalandneuropathicpainsystematicreviewandmetaanalysisofclinicalevidence |